NCT05501717View on ClinicalTrials.gov

Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 16, 2022

Primary Completion Date

October 30, 2026

Study Completion Date

October 30, 2026

Conditions
Healthy
Interventions
DRUG

ALXN2030

ALXN2030 will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.

DRUG

Placebo

Placebo will be administered subcutaneously as a single dose either as a manual SC injection or as an SC infusion via a syringe pump.

Trial Locations (1)

HA1 3UJ

Research Site, Harrow

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY